Evidence mapPaperPMID 40084006Full record

ReviewHeliyon2025

Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin.

Piero Alex Silva-Pinto, Janaína Teixeira Costa de Pontes, Brigitte Aguilar-Morón, Christian Shleider Carnero Canales, Fernando Rogério Pavan, Cesar Augusto Roque-Borda

Abstract readReview
In one paragraph

Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Process Optimization ofAntioxidants (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Drug design, development and therapy · 2026
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Piero Alex Silva-PintoVicerrectorado de Investigación, Universidad Católica de Santa María de Arequipa, Arequipa, 04000, Republic of Peru.
Janaína Teixeira Costa de PontesDepartment of Biological Sciences, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, 14800-900, SP, Brazil.
Brigitte Aguilar-MorónFacultad de Ingeniería de Procesos - Universidad Nacional de San Agustín, Arequipa, Arequipa, Republic of Peru.
Christian Shleider Carnero CanalesLaboratorio BIOMET, Facultad de Ciencias de la Universidad Nacional de Ingeniería, Av. Túpac Amaru 210, Rímac, Lima, Republic of Peru.
Fernando Rogério PavanDepartment of Biological Sciences, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, 14800-900, SP, Brazil.
Cesar Augusto Roque-BordaVicerrectorado de Investigación, Universidad Católica de Santa María de Arequipa, Arequipa, 04000, Republic of Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quercetin, a flavonoid known for its potent antioxidant and anti-inflammatory properties, has gained attention in cancer therapy due to its ability to modulate key molecular pathways involved in tumor progression and immune evasion. This review provides a comprehensive analysis of quercetin's effects on pathways such as PI3K/Akt/mTOR, MAPK/ERK, NF-κB, and JAK/STAT, which are central to cancer cell survival, proliferation, and apoptosis. Through inhibition of PI3K/Akt/mTOR and MAPK/ERK signaling, quercetin promotes apoptosis and reduces proliferation specifically in cancer cells while sparing healthy cells. Additionally, quercetin downregulates NF-κB activity and modulates JAK/STAT signaling, enhancing immune recognition of cancer cells and decreasing inflammation in the tumor microenvironment. Emerging nanoformulation strategies are also discussed, highlighting how nanotechnology can improve quercetin's bioavailability and targeting capabilities. Unlike other reviews, this work uniquely integrates molecular insights with cutting-edge nanoformulations, showcasing quercetin's dual potential as a therapeutic agent and an immune modulator in the evolving landscape of cancer treatment. This review underscores quercetin's multifaceted role in cancer treatment and suggests future directions to optimize its clinical efficacy, particularly in combination with conventional therapies.

Indexed as

AntioxidantsFlavonoidsJAK/STATNanoformulationsNF-κBPI3K/Akt/mTORQuercetinSignaling pathwaysTumor microenvironment

Identifiers

PMID40084006
PMCPMC11904581

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.